Navigation Links
Panel of Osteoarthritis Experts Develops Optimal Profile of Exogenous Hyaluronic Acid

NEWTOWN SQUARE, Pa., Nov. 18 /PRNewswire/ -- A panel of osteoarthritis (OA) key opinion leaders has developed a consensus of the optimal exogenous hyaluronic acid (HA) treatment. This consensus was achieved by utilizing what the experts referred to as BioRestorative(TM) Profiling. This profiling examines HAs on the basis of their mimicking the body's natural HA. "BioRestorative(TM)" describes the features of the ideal HA product, based on the treatment goals of symptom relief, improvement in function, and improved quality of life. In a comparison of available HA products, EUFLEXXA® (1% sodium hyaluronate) best matched the BioRestorative profile. Results of the panel's discussion were published in an independent educational publication authored by members of The Institute for Clinical Care, accessible at The report was sponsored by Ferring Pharmaceuticals Inc., the maker of EUFLEXXA®, and published by Dardine & Associates, LLC.

Features of the Ideal HA Product

The panel hypothesized that the exogenous HA product likely to yield the best results in OA treatment is one that most closely resembles endogenous human HA in all ways, including size, structure and molecular weight. The ideal HA would have high viscosity and high molecular weight. When injected, it would supplement the synovial fluid inside the knee and lubricate and protect the joint. The product would also be as pure as possible, containing no contaminants or animal proteins. A low protein concentration lowers the risk of inflammatory reactions and pseudosepsis.

"The term 'BioRestorative' suggests that an ideal HA has a restorative effect on naturally occurring synovial fluid in the joint," said panel leader Dr. Jeffrey E. Rosen, Chairman, Department of Orthopaedics and Physical Medicine & Rehabilitation at New York Hospital Queens. "Of the currently marketed HA products, non-avian EUFLEXXA® most closely fits the BioRestorative profile. It has ultra-high purity, high molecular weight, and minimal protein content."

About HA Treatment

In the joint, HA is essential to water balance, viscosity, lubrication and the structure of cartilage. It provides a cushion to protect the inside of the joint from mechanical damage and acts as a shock-absorbing fluid and regulator of water and metabolites. In synovial fluid, HA binds to other molecules, helping it withstand weight-bearing force and movement of the joint. Injections into the joint have been shown to provide long-term improvement of the quantitative and qualitative properties of endogenous HA, increasing joint lubrication and reducing pain.(1) Most current products are avian-derived, and two are bioengineered via fermentation of bacteria.

About The Institute for Clinical Care

The Institute for Clinical Care was established in 2005 to facilitate the development and dissemination of timely and clinically relevant educational programming sponsored by respected institutional and nonprofit providers of continuing education for healthcare providers. The clinical authorities with whom the Institute works are recognized leaders in their field. It is under their direction and with their contribution and approval that the content for the Institute's educational offerings are developed.

(1) Hempfling H. Intra-articular hyaluronic acid after knee arthroscopy: a two-year study. Knee Surg Sports Traumatol Arthrosc. 2007;14(3):537-546.

SOURCE The Institute for Clinical Care

SOURCE The Institute for Clinical Care
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Anesiva Receives Positive Nasdaq Hearing Panel Determination for Continued Listing
2. Asthmatx Receives FDA Advisory Panel Recommendation for Approvable with Conditions for Bronchial Thermoplasty with the Alair(R) System for Severe Asthma
3. Varian Medical Systems to Exhibit a Wide Selection of Flat Panel X-Ray Image Detectors and X-Ray Tubes at the CMEF Show in Chengdu, China
4. Rules-Based Medicine Introduces CardiovascularMAP(TM) Multiplex Biomarker Panel to Aid CVD Drug Development
5. GlaxoSmithKline Receives Unanimous FDA Panel Approval Recommendation for VOTRIENT(TM)
6. FDA Advisory Panel Makes Favorable Recommendation for GlaxoSmithKline and Genmabs ARZERRA(TM) (ofatumumab)
7. FDA Advisory Panel Recommends Approval of the SEDASYS(R) System
8. Savient Announces FDAs Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients
9. AlphaDetail AlphaPulse(TM): Most Practicing Physicians React Positively to FDA Panels Recommendation for Additional Cardiovascular Safety Trials for New Diabetes Medications.
10. Data Presented at American Headache Societys Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics Tezampanel
11. TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel
Post Your Comments:
(Date:11/26/2015)... DUBLIN , Nov. 26, 2015 ... the addition of the "2016 Future Horizons ... Monitoring (TDM) Market: Supplier Shares, Country Segment Forecasts, ... offering. --> ... comprehensive analysis of the Japanese therapeutic drug monitoring ...
(Date:11/26/2015)... , November 26, 2015 ... Juntendo universitetssjukhus ser potential att använda SyMRI ... (MR-bilder) för patienter med multipel skleros ... forskningsavtal med SyntheticMR AB för att kunna ... på sjukhuset. Med SyMRI kan man generera ...
(Date:11/26/2015)... -- ) has announced the ... Viscosity Drugs" report to their offering. ... of the "Self Administration of High Viscosity ... Research and Markets ( ) has ... of High Viscosity Drugs" report to their ...
Breaking Medicine Technology:
(Date:11/30/2015)... Juan, Puerto Rico (PRWEB) , ... November 30, 2015 , ... ... an active part of the San Juan Beauty Show held on November 8th and ... event was attended by media personalities, hair artists, renowned beauticians and top of the ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... their strategic partnership at the Radiological Society of North America (RSNA) 2015 ... global providers of cutting-edge dictation and speech-enabled documentation software, announced their partnership ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... announces the Unstoppable Swappables, a household invention that provides an economical and easy ... a year and is growing at 2.6%," says Scott Cooper, CEO and Creative ...
(Date:11/29/2015)... Clarkston, Metamora, Michigan (PRWEB) , ... ... ... Excellence is once again accredited by the American Institute of Ultrasound in ... that allows practices to demonstrate that they meet or exceed nationally recognized ...
(Date:11/29/2015)... ... 2015 , ... Khanna Vision Institute based in Los Angeles, announced that Dr. ... 2015. Peer Certification by the Board is done so the public knows that the ... obtained after the completion of three years of training or Residency in Ophthalmology. This ...
Breaking Medicine News(10 mins):